US Patent

US12171739 — N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

Composition of Matter · Assigned to Array Biopharma Inc · Expires 2026-11-15 · 0y remaining

Vulnerability score 35/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a class of compounds useful as type I receptor tyrosine kinase inhibitors for treating hyperproliferative diseases in mammals.

USPTO Abstract

This invention provides compounds of Formula I wherein B, G, A, E, R 1 , R 2 , R 3 , m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

Drugs covered by this patent

Patent Metadata

Patent number
US12171739
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-11-15
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Array Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.